Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mayne Pharma Group ( (AU:MYX) ) just unveiled an announcement.
Vanguard Group, through The Vanguard Group, Inc. and its controlled entities including Vanguard Investments Australia Ltd., has notified Mayne Pharma Group Limited that it has ceased to be a substantial holder in the company. As of 2 February 2026, Vanguard’s voting power in Mayne Pharma stands at 4.972%, down from a previously higher level that met Australia’s substantial holding threshold, indicating a reduction in its shareholding but continued, albeit smaller, institutional investment presence in the stock.
The most recent analyst rating on (AU:MYX) stock is a Sell with a A$2.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is an Australian pharmaceutical company focused on the development and manufacture of branded and generic medicines. It operates in the healthcare sector, supplying specialty and generic pharmaceutical products to domestic and international markets.
Average Trading Volume: 501,781
Technical Sentiment Signal: Sell
Current Market Cap: A$221.8M
For detailed information about MYX stock, go to TipRanks’ Stock Analysis page.